By Jessica DiNapoli and Ross Kerber NEW YORK (Reuters) – Approximately 57% of investor votes endorsed the salary of executives at healthcare company Johnson & Johnson (NYSE 🙂 for 2020, a low level of support for a proposal that most shareholders usually approve. The scant support, excluding abstentions, for the non-binding proposal comes after the Illinois State Treasurer’s Office urged other shareholders to vote “No” on the company’s salary practices, that is, because J&J set aside certain litigation costs when calculating executive compensation. even from the US opioid epidemic Representative consultants Glass Lewis and Institutional Shareholder Services Inc also advised against J&J pay.
Disclaimer: Fusion Media wishes to remind you that the data contained on this website is not necessarily accurate or in real time. All CFDs (stocks, indices, futures) and Forex prices are not provided by exchanges but by market makers, so the prices may not be accurate and may differ from the actual market price, which means that prices are indicative and not appropriate for commercial purposes. Therefore, Fusion Media assumes no responsibility for any business losses you may incur as a result of the use of this data. Fusion Media or anyone involved with Fusion Media will accept no responsibility for loss or damage as a result of reliance on information, including data, quotes, charts, and buy / sell signals contained on this website. Be fully informed about the risks and costs associated with trading the financial markets, it is one of the riskiest forms of investment possible.